Emergency use authorization indicated for those who have been exposed to SARS-CoV-2 and have an immunocompromising condition
Neutralizing Monoclonal Antibody Combo Treats Mild, Moderate COVID-19
For those at high risk, COVID-19-related hospitalization or death from any cause reduced with bamlanivimab/etesevimab versus placebo
Neither Remdesivir Nor HCQ Affect Viral Clearance in COVID-19
No significant difference seen for in-hospital mortality among those receiving remdesivir, hydroxychloroquine, standard of care
Cardiovascular Drugs Do Not Impact COVID-19 Outcomes
Authors say patients even with COVID-19 should continue taking cardiovascular drugs as prescribed
Monoclonal Antibodies for COVID-19 Effective for Transplant Patients
Favorable outcomes, minimal adverse effects seen in solid organ transplant recipients who received monoclonal antibody therapy for COVID-19
U.S. to Spend $3.2 Billion to Help Develop Antiviral Pills for COVID-19
Oral medications patients take when symptoms first appear are being tested, but initial results are not expected for several months
Methotrexate May Impair Immune Response to mRNA COVID-19 Vaccine
Poorer humoral, cellular immune responses seen in patients receiving methotrexate for immune-mediated inflammatory disease
Meds Used for Hospitalized COVID-19 Patients Shifted Over 2020
Dexamethasone and remdesivir use grew substantially, while azithromycin and hydroxychloroquine both declined from early peaks
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
COVID-19 Pill Could Be Available Later This Year: Pfizer CEO
If clinical trials are successful and the FDA approves the drug, it could be available across the United States later in 2021